文献速递淋巴瘤

t(14;18)阴性滤泡性淋巴瘤的遗传异质性

Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease.
PubMed 文献 · Blood Adv · 2020-01-01

基因突变谱与经典t(14;18)阳性FL部分重叠但频率不同,STAT6突变最常见(57%),并可分为两个分子亚群。腹股沟起病者具有独特的临床病理和遗传特征。

要点

  • t(14;18)阴性FL多见于女性,71%为早期,预后良好。
  • STAT6突变率57%,显著高于经典FL,且缺乏MYD88、NOTCH2等突变。
  • 腹股沟起病者弥漫生长、STAT6突变和CD23表达更常见,CNA较少。

核心结论

  • t(14;18)阴性FL是一种遗传异质性疾病,其特征不同于经典FL、结内边缘区淋巴瘤和儿童型FL。

主要发现

  • 女性多见(男:女=1:2),71%为早期临床阶段,预后极好。
  • 突变频率:STAT6 57%、CREBBP 49%、TNFRSF14 39%、KMT2D 27%。
  • 与经典FL相比,STAT6突变显著更多,且缺乏MYD88、NOTCH2、MEF2B和MAP2K1突变。
  • 识别出两个分子簇:簇A以TNFRSF14突变/1p36改变(96%)和表观遗传调控因子突变为特征,常伴6q21-24缺失;簇B遗传改变少,但存在STAT6与CREBBP突变/16p改变共存且无TNFRSF14和EZH2突变的亚组(65%)。
  • 腹股沟起病者(20/50,40%)弥漫生长模式、STAT6突变和CD23表达频率更高,CNA数量更少(每例5.1 vs 9.1,P < .05);STAT6突变与CD23表达正相关(P < .001)。

关键数值与推荐

  • STAT6突变与CD23表达正相关(P < .001)。
  • 腹股沟起病者CNA数量每例5.1 vs 9.1(P < .05)。
  • BCL6重排见于10/45(22%)病例,未聚集。

临床怎么用

  • t(14;18)阴性FL患者预后良好,可考虑减少治疗强度。
  • STAT6突变和CD23表达可能有助于识别特定亚群。
  • 腹股沟起病伴弥漫生长模式者应关注其独特遗传特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fifty-five cases of t(14;18)- follicular lymphoma (FL) were genetically characterized by targeted sequencing and copy number (CN) arrays. t(14;18)- FL predominated in women (M/F 1:2); patients often presented during early clinical stages (71%), and had excellent prognoses. Overall, t(14;18)- FL displayed CN alterations (CNAs) and gene mutations carried by conventional t(14;18)+ FL (cFL), but with different frequencies. The most frequently mutated gene was STAT6 (57%) followed by CREBBP (49%), TNFRSF14 (39%), and KMT2D (27%). t(14;18)- FL showed significantly more STAT6 mutations and lacked MYD88, NOTCH2, MEF2B, and MAP2K1 mutations compared with cFL, nodal marginal zone lymphoma (NMZL), and pediatric-type FL (PTFL). We identified 2 molecular clusters. Cluster A was characterized by TNFRSF14 mutations/1p36 alterations (96%) and frequent mutations in epigenetic regulators, with recurrent loss of 6q21-24 sharing many features with cFL. Cluster B showed few genetic alterations; however, a subgroup with STAT6 mutations concurrent with CREBBP mutations/16p alterations without TNFRSF14 and EZH2 mutations was noted (65%). These 2 molecular clusters did not distinguish cases by inguinal localization, growth pattern, or presence of STAT6 mutations. BCL6 rearrangements were demonstrated in 10 of 45 (22%) cases and did not cluster together. Cases with predominantly inguinal presentation (20 of 50; 40%) had a higher frequency of diffuse growth pattern, STAT6 mutations, CD23 expression, and a lower number of CNAs, in comparison with noninguinal cases (5.1 vs 9.1 alterations per case; P < .05). STAT6 mutations showed a positive correlation with CD23 expression (P < .001). In summary, t(14;18)- FL is genetically a heterogeneous disorder with features that differ from cFL, NMZL, and PTFL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Nann D, Ramis-Zaldivar JE, Müller I, et al. Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease. Blood Adv. 2020. PMID: 33211828. doi:10.1182/bloodadvances.2020002944

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。